Free Trial

James Molloy Analyst Performance

Analyst at Alliance Global Partners

James Molloy is a stock analyst at Alliance Global Partners in the medical sector, covering 6 publicly traded companies. Over the past year, James Molloy has issued 1 stock ratings, including and buy recommendations. While full access to James Molloy's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights James Molloy's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 11 Years
Buy Recommendations
100.00% 8 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%8 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
83.3% of companies on NASDAQ
5 companies
NYSEAMERICAN
16.7% of companies on NYSEAMERICAN
1 company

James Molloy, an analyst at Alliance Global Partners, currently covers 6 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

James Molloy of Alliance Global Partners specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
33.3%
MED PRODUCTS
2 companies
33.3%
PHARMACEUTICAL PREPARATIONS
1 company
16.7%
BIOTECHNOLOGY
1 company
16.7%

James Molloy's Ratings History at Alliance Global Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Soligenix Inc. stock logo
SNGX
Soligenix
7/16/2025Lower Price Target$1.30$6.00Buy
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3/6/2025Reiterated Rating$0.31$3.50Buy
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
1/13/2025Initiated Coverage$53.69$212.50Buy